449 related articles for article (PubMed ID: 32945172)
1. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
2. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
3. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
McGregor BA; Sonpavde G
Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
[No Abstract] [Full Text] [Related]
4. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
5. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
6. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
7. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
Wong RL; Yu EY
Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
[TBL] [Abstract][Full Text] [Related]
8. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
9. Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
Pace A; Brower B; Conway D; Leis D
Clin J Oncol Nurs; 2021 Apr; 25(2):E1-E9. PubMed ID: 33739346
[TBL] [Abstract][Full Text] [Related]
10. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
[TBL] [Abstract][Full Text] [Related]
11. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
12. Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M; Rosenberg JE
Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
15. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
Hashimoto H; Tanaka Y; Murata M; Ito T
Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
[TBL] [Abstract][Full Text] [Related]
16. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
[TBL] [Abstract][Full Text] [Related]
17. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
[TBL] [Abstract][Full Text] [Related]
18. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
19. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
20. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA; Sonpavde GP; Kwak L; Regan MM; Gao X; Hvidsten H; Mantia CM; Wei XX; Berchuck JE; Berg SA; Ravi PK; Michaelson MD; Choueiri TK; Bellmunt J
Ann Oncol; 2024 Jan; 35(1):91-97. PubMed ID: 37871703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
